Jyong Biotech Proposes Texas Manufacturing Facility
The Taiwan-based company plans to build a new U.S. facility to support future drug operations.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Do you support your state offering tax incentives to attract new pharmaceutical manufacturing facilities?
Jyong Biotech has submitted a formal facility and operations plan to Texas state authorities to establish a new manufacturing site. This move aims to bolster the company's U.S. presence and support the future commercialization of its drug pipeline.
Why it matters
Establishing a domestic facility allows the firm to scale operations and better navigate market conditions for its drug candidates. The expansion is strategically focused on leveraging the state's tax incentives and manufacturing climate.
Jyong Biotech currently reports that 54.8% of actively managed BPH/LUTS patients use chemical medications, while 35% remain in watchful waiting. Approximately 9.1% of these actively managed patients choose to discontinue therapy.
The players
Jyong Biotech
This Taiwan-based company is a pharmaceutical developer that was originally established in 2002.
The details
The proposal focuses on building a facility with full pharmaceutical manufacturing capabilities, with potential for health supplement production lines. Jyong Biotech, which was founded in 2002, chose Texas specifically for its favorable land costs, tax exemptions, and incentives.
Timeline
2002: Jyong Biotech is established.
2012: Review of BPH-related LUTS patients is published.
2015: Report on the management of U.S. men for BPH/LUTS is released.
October 15, 2026: The company announces its proposed Texas facility.
Market Landscape
Jyong Biotech is entering a competitive landscape by positioning its manufacturing base in a state known for attracting global life science companies. This expansion mirrors the broader industry trend of foreign firms seeking to localize U.S. production through state-level incentives.
While the proposal does not immediately change drug availability, it signals the company's intent to increase its U.S. presence for future treatments. Consumers may eventually see new product offerings if the facility receives approval and proceeds to full-scale operations.
The takeaway
Jyong Biotech is moving toward a U.S.-based manufacturing model to support its drug candidate pipeline. The company is currently transitioning from its foundational research roots toward potential commercialization activities.
Further reading
For more information on regional industry developments, visit the Texas Healthcare section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you support your state offering tax incentives to attract new pharmaceutical manufacturing facilities?
